CTLA4 and rheumatoid arthritis: However, RA patients under TNF-α inhibitors and CTLA-4-Ig showed a significant lower anti-RBD IgG median titer compared to HCWs (p = 0.0034 and p < 0.0001, respectively) (Figure 2B).